WHO moves to roll out first malaria vaccine in Africa
29th Jul, 2022
World Health Organization announced the rollout of the world's first authorized malaria vaccine in three African countries
About the Vaccine
- The WHO recommendation is for RTS, S - or Mosquirix- a vaccine developed by British drug maker GlaxoSmithKline.
- The active ingredient in Mosquirix is made up of proteins found on the surface of Plasmodium falciparum parasites (PFP).
- RTS, S aims to start the immune system in the early stages of malaria when PFP enters the bloodstream through a mosquito bite and infects liver cells.
- The RTS malaria vaccine, S / AS01 is used to prevent falciparum malariain children living in regions with moderate to high transmission.
- Falciparum, the most common form of malaria in Africa.
- It is the first vaccine and the only one that shows partial protection against young children.
- The malaria vaccine should be given in a 4-dose program to children from five months of age to reduce the incidence of malaria and the burden.
- The vaccine adds to the development of the malaria tool and can help get malaria control back on track.
- It also helps prevent liver infection with the Hepatitis B virus.
- Malaria is a life-threatening disease caused by parasites transmitted to humans through the bite of female Anopheles mosquitoes.
- It is preventable and curable.
- Over the past two decades, 11 countries have been WHO-certified free of malaria:
- United Arab Emirates (2007)
- Morocco (2010)
- Turkmenistan (2010)
- Armenia (2011)
- Sri Lanka (2016)
- Kyrgyzstan (2016)
- Paraguay (2018)
- Uzbekistan (2018)
- Algeria (2019)
- Argentina (2019)
- El Salvador (2021)